G&E HERBAL BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.1 TWD | +1.20% |
|
+0.68% | -4.37% |
| Sales 2022 | 64.61M 1.98M | Sales 2023 | 181M 5.57M | Capitalization | 3.44B 106M |
|---|---|---|---|---|---|
| Net income 2022 | 7M 215K | Net income 2023 | 72M 2.21M | EV / Sales 2022 | 42.8 x |
| Net cash position 2022 | 206M 6.32M | Net cash position 2023 | 311M 9.55M | EV / Sales 2023 | 17.2 x |
| P/E ratio 2022 |
403
x | P/E ratio 2023 |
47.5
x | Employees | 37 |
| Yield 2022 * |
-
| Yield 2023 |
0.92% | Free-Float | 49.84% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.20% | ||
| 1 week | +0.68% | ||
| Current month | -0.67% | ||
| 1 month | +3.68% | ||
| 3 months | +1.20% | ||
| 6 months | +8.24% | ||
| Current year | -4.37% |
1 week
57.10
59.90
1 month
57.0062.30
Current year
55.0062.80
1 year
53.0083.50
3 years
22.5083.50
5 years
21.4083.50
10 years
21.40167.49
| Managers | Title | Age | Since |
|---|---|---|---|
Kuo Wha Kuo
CEO | Chief Executive Officer | - | 02-08-05 |
Chang I Hung
DFI | Director of Finance/CFO | - | - |
Sheng Hui Chou
IRC | Investor Relations Contact | - | 07-05-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kuo Wha Kuo
CEO | Chief Executive Officer | - | 02-08-05 |
Chun Nung Huang
BRD | Director/Board Member | - | 19-06-13 |
Chih Tsung Lin
BRD | Director/Board Member | - | 19-06-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 59.1 | +1.20% | 11,184 |
| 24-04-23 | 58.4 | +0.34% | 19,268 |
| 24-04-22 | 58.2 | -0.68% | 29,215 |
| 24-04-19 | 58.6 | -0.17% | 34,015 |
| 24-04-18 | 58.7 | 0.00% | 20,024 |
End-of-day quote Taipei Exchange, April 23, 2024
More quotes
G&E Herbal Biotechnology Co., Ltd is a Taiwan-based company principally engaged in the research and development, manufacture and distribution of health care food products, functional skin care products and pharmaceutical products. Its health care food products include accessory food products and capsules for cancer and urogenital disorder. The Company also provides botanical medicines for cancers and liver diseases. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -4.37% | 101M | |
| +38.08% | 6.05B | |
| -16.43% | 4.45B | |
| -12.46% | 3.06B | |
| -0.21% | 3.04B | |
| -0.59% | 2.58B | |
| +34.54% | 1.79B | |
| +0.93% | 1.66B | |
| -10.63% | 1.63B | |
| -12.50% | 1.54B |
- Stock Market
- Equities
- 4911 Stock
